Press Release
Sector Spotlight: Orphan Drug Developers With Significant Upside
–News Direct–
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record of strong recoveries, with the sector typically seeing double-digit gains after a downturn. This is something investors shouldnt ignore.
This recent turnaround can be credited to a robust increase in fundraising efforts and an uptick in IPOs, reaching levels not seen since the peak of the mid-pandemic market boom.
According to the Financial Times, drug developers raised $6 billion in equity capital markets in January, the largest total since February 2021 a period when biotech stocks hit their all-time high. Moreover, the SPDR S&P Biotech ETF (XBI) returned 28.7% over the past six months alone, clearly illustrating investors' rising confidence in the biotech rebound.
Identifying biotech stocks with the potential to deliver superior returns is no easy feat. There are specific milestones that companies can achieve to signal positive momentum to investors. For example, smaller biotech companies may have received the nod from regulatory authorities such as the FDA, or new breakthroughs from clinical trials, to offer a compelling investment opportunity.
With that in mind, two stocks that investors should consider looking at are Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA).
Cardiol Therapeutics lead product is CardiolRx, a small molecule therapy that appears on track to bring major disruption to the pericarditis market.
CardiolRx received a vote of confidence as it was granted Orphan Drug Designation (ODD) by the FDA for the treatment of pericarditis back in February, illustrating the potential of the drug. Apart from providing a seven-year term of market exclusivity upon final FDA approval, the ODD also positions Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees, and certain tax credits.
The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. There are approximately 160,000 cases of recurrent pericarditis in the U.S. annually, which includes 38,000 cases with a recurrence. Having secured FDA approval, Cardiol Therapeutics is an exemplary company likely to attract biotech investors seeking assurance in smaller firms.
While the stock had a significant rally on the backdrop of this news and continues to show strength, we believe that there is still potential for further upside.
Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) is expected to release topline data in June for its Phase 2 MAvERIC-Pilot clinical trial, which if positive, could unlock significant shareholder value. Several analysts have already indicated that they are highly optimistic that the data could be a catalyst, with one analyst noting that CardiolRxs potential to be a safe, new approach to RP (recurrent pericarditis) treatment is underappreciated.
CardiolRx stands out when compared to the only FDA-approved therapy because it is administered orally and expected to be offered as a first-line therapy for pericarditis, opening it up to an even bigger opportunity as it could be prescribed at the first occurrence.
Orphan drugs have become lucrative business opportunities because these drugs command premium drug pricing, with the average price for an orphan drug at $32,000 per year per patient according to a 2021 study published in the journal Rare Diseases & Journal of Orphan Drugs.
That could explain why analysts who have been tracking CRDL are so bullish on the stock. For instance, Joe Gantoss of Chimera Research Group says he wont be surprised to see Cardiols price break past the 3-year high at $4.96, while analyst Vernon Bernardino of H.C. Wainwright & Co. reiterated their Buy rating and issued a $9.00 price target.
That would imply that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from its current share price.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) offers some insight into the revenue potential of an orphan drug that treats recurrent pericarditis.
So far, KNSA has had a great run, gaining about 36% over the past year and trading at about $18.00 per share despite challenges in the sector. It is currently valued at $1.3 billion. Kiniksas portfolio of assets includes ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis.
For some context, the FDA granted Breakthrough Therapy designation to ARCALYST for recurrent pericarditis in 2019; the FDA granted Orphan Drug exclusivity to ARCALYST in March 2021 for the treatment of recurrent pericarditis and a reduction in the risk of recurrence in adults and pediatric patients 12 years of age and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.
Sales of ARCALYST were $38.5 million in 2021; $122.5 million in 2022; $233.2 million in 2023 further reaffirming the massive revenue potential for treating recurrent pericarditis. For the first quarter of 2024, ARCALYST sales were $78.9 million representing 85% year-over-year growth.
Furthermore, since its launch in April 2021, approximately 2,000 prescribers have written ARCALYST prescriptions for recurrent pericarditis, illustrating the massive demand for effective recurrent pericarditis therapies.
Going forward, Kiniksa anticipates that it will bring in between $370 million and $390 million in 2024, up from the earlier guidance of $360 million to $380 million. The revised outlook represents roughly 63% year-over-year growth at the midpoint.
Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cardiol Therapeutics to assist in the production and distribution of content related to CRDL. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
Contact Details
RazorPitch Inc
Mark McKelvie
+1 585-301-7700
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/sector-spotlight-orphan-drug-developers-with-significant-upside-473277125
RazorPitch CRDL, KNSA
COMTEX_453280304/2655/2024-06-03T07:03:00
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Vape Buy Launches New Online Platform to Bridge the Gap Between Single-Use and Rechargeable Vaping
Vape Buy, a premier UK online vape retailer, announces the launch of its new website. The platform is designed to streamline the transition for customers moving from standard disposables to TPD-compliant Big Puff vapes and refillable pod systems.
London, United Kingdom, 26th Jan 2026 – Vape Buy, a premier UK online vape retailer, announces the launch of its new website. The platform is designed to streamline the transition for customers moving from standard disposables to TPD-compliant Big Puff vapes and refillable pod systems.
The new website features a streamlined, mobile-optimised design that prioritises speed and accessibility. It categorises the retailer’s extensive inventory into intuitive sections, including Big Puff Vapes (6K, 10K, 20K+ capacities), Nic Salts, Pod Vape Kits, and Shortfill E-Liquids. Recognising the industry shift towards more sustainable options, Vape Buy has positioned itself as a specialist in bridging the gap between single-use bars and advanced rechargeable kits.
To ensure compliance and speed, the site utilises a lightweight, custom-built age verification system and optimised infrastructure to deliver a fast browsing experience. Customers across the UK benefit from rapid dispatch on all orders, with a focus on delivering the latest hardware from industry leaders such as Vaporesso, OXVA, SMOK, and GeekVape.
“We want to simplify the vaping journey for our customers,” said a spokesperson for Vape Buy. “The market is moving away from traditional single-use disposables towards higher capacity, TPD-compliant Big Puff devices and refillable pods. Our new platform makes it effortless for users to find these cost-effective alternatives. Whether a customer needs a Hayati Pro, an IVG 2400, or a bottle of Elfliq, our goal is to get it to their door quickly and efficiently.”
Vape Buy stocks a curated selection of genuine products sourced directly from trusted manufacturers. The inventory includes the latest releases from Lost Mary, SKE Crystal, and Elux, alongside a vast library of e-liquid flavours ranging from classic tobacco to popular fruit blends. The site operates with strict adherence to UK regulations, ensuring all products are genuine and age-verified.
Vape Buy invites adult smokers and existing vapers to visit the new online store to explore the range of high-capacity devices and premium e-liquids.
About Vape Buy
Vape Buy is a UK-based online vape store dedicated to providing high-quality vaping hardware and e-liquids. With a focus on value and compliance, the company specialises in Big Puff vapes and refillable pod kits, helping customers transition away from expensive single-use disposables. Headquartered in London, Vape Buy offers fast UK shipping and dedicated customer support to ensure a seamless purchasing experience.
More Information
To learn more about Vape Buy and the launch of its new website, please visit https://vapebuy.co.uk/.
Media Contact
Organization: Revo 2 Evo LTD T/A Vape Buy
Contact Person: Vape Buy
Website: https://vapebuy.co.uk/
Email: Send Email
Contact Number: +442071013143
Address:128 City Road
City: London
Country:United Kingdom
Release id:40614
The post Vape Buy Launches New Online Platform to Bridge the Gap Between Single-Use and Rechargeable Vaping appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Doctors Behind Proud Urology’s Growth, Dr. Jin-mo Koo and Dr. In-sung Hwang, Launch Highest Urology Clinic in Seoul with Advanced Sterile Systems
Seoul, Korea South, 26th Jan 2026 – Highest Urology Clinic officially announced its grand opening on January 19 in the heart of Seoul. The clinic is led by Representative Directors Dr. Jin-mo Koo and Dr. In-sung Hwang, the visionaries widely recognized for driving the unprecedented growth and success of Proud Urology. Their new venture is dedicated to establishing a global standard in male reconstructive and aesthetic urology through advanced medical infrastructure.
To ensure the highest level of patient safety, the clinic has implemented a University-Hospital Level Sterile Surgery System. The facility features four independent operating rooms equipped with Positive Pressure Air Conditioning, a specialized technology that maintains a zero-infection environment by blocking external pollutants and fine dust. This high-standard infrastructure is essential for the clinic’s specialized procedures involving surgical implants and grafts.
Dr. Jin-mo Koo, a leading authority in male reconstruction, brings his extensive clinical expertise in the application of MegaDerm (Acellular Dermal Matrix) and MegaFill. His precision-focused approach, backed by years of clinical data, ensures natural and safe outcomes. Co-representative Dr. In-sung Hwang complements this with his expertise in gynecomastia correction and male body contouring, merging functional restoration with aesthetic excellence.
“Our opening on January 19 marks a new era in men’s healthcare,” said the Directors. “By integrating the clinical expertise we developed while leading Proud Urology with a state-of-the-art sterile environment, we are committed to providing a premier medical experience that both domestic and international patients can trust.”
About Highest Urology Clinic: Highest Urology Clinic is a premier medical institution in Seoul specializing in advanced urological surgery and men’s health. Led by industry experts Dr. Jin-mo Koo and Dr. In-sung Hwang, the clinic provides comprehensive solutions in reconstructive and aesthetic urology, supported by a university-grade sterile infrastructure.
Address : 14F & 15F, 655, Seolleung-ro, Gangnam-gu, Seoul, Republic of Korea
Learn more at : www.highsturology.co.kr
Media Contact
Organization: Highst Urology Clinic
Contact Person: Sung
Website: https://www.highsturology.co.kr/
Email: Send Email
City: Seoul
Country:Korea South
Release id:40586
The post Doctors Behind Proud Urology’s Growth, Dr. Jin-mo Koo and Dr. In-sung Hwang, Launch Highest Urology Clinic in Seoul with Advanced Sterile Systems appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Dr. Ijeoma Esther Nnamdi: Redefining Global Leadership, Empowering Women and Next-Generation Leaders
Nigeria, 26th Jan 2026 –Grounded in executive experience as Group General Manager to the helm of international organizations as Strategic Country Director/Head, Dr. Ijeoma Esther Nnamdi—Global Keynote Speaker and Human Capacity Development Expert—is redefining leadership by advancing excellence, gender equity and transformative social impact across Africa and beyond. A seasoned author and co-author of bestselling books published in the United States, India, Indonesia, the Philippines and Zimbabwe; her career trajectory demonstrates strategic depth, adaptability and operational excellence. She is particularly respected for her commitment to empowering women and positioning the girl child for leadership within systems where access and opportunity remain limited.
Anchored in the conviction that leadership must be intentional, strategic and results-driven; Her professional work centres on the design and execution of high-impact initiatives that strengthen institutions, build human capital and address structural barriers that restrict women and girls. Her leadership approach integrates policy intelligence, stakeholder management and executional precision, earning her recognition as a trusted voice across government, civil society, faith-based platforms, corporate institutions and international development ecosystems.
On 25 November 2025, Dr. Ijeoma Esther Nnamdi led the globally resonant “Say No to Child Marriage” campaign under the theme “Her Dreams Matter More Than Your Traditions.” The campaign strategically challenged deeply entrenched harmful practices while repositioning the girl child as a vital global asset whose education, agency and aspirations must be protected and prioritized.
As a Global Keynote Speaker, her engagements have reached audiences in fifteen countries across Asia, North America, Europe, Australia, and Africa. Her influence has been recognized through more than 100 awards for leadership and impact. She has delivered transformational insights on over a thousand platforms, including leadership summits, policy forums, academic institutions and women faith-focused development conferences. Her speaking style is noted for its clarity, authority and electrifying effect, equipping leaders to build inclusive, high-performing and future-ready systems.
Dr. Ijeoma Esther Nnamdi is the author of LEAD BEYOND, distributed to teenage girls across seven secondary schools and YOUTHFUL WITHOUT BLEMISH, which has been a tool for training in faith-based youth leadership programs. She has more than 30 publications. Her body of work reflects a consistent philosophy that empowerment must begin early, be intentional and be sustained—creating pathways that enable women and girls not merely to survive, but to lead beyond societal limitations.
Her leadership is described as principled, courageous and generational, positioning her as a significant force in global discourse on leadership, equity and human development.
Social Media Links :
https://www.facebook.com/share/1HootmxJdE/
https://www.linkedin.com/in/dr-ijeoma-esther-nnamdi-362009148
https://www.instagram.com/iamesthernnamdi
Book Store : https://selar.com/m/Inspirationals
Media Contact
Organization: Mummy and I Magazine
Contact Person: Dr. Ijeoma Esther Nnamdi
Website: https://www.instagram.com/mummyand_i
Email: Send Email
Contact Number: +2348137890242
Country:Nigeria
Release id:40582
The post Dr. Ijeoma Esther Nnamdi: Redefining Global Leadership, Empowering Women and Next-Generation Leaders appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Vape Buy Launches New Online Platform to Bridge the Gap Between Single-Use and Rechargeable Vaping
Doctors Behind Proud Urology’s Growth, Dr. Jin-mo Koo and Dr. In-sung Hwang, Launch Highest Urology Clinic in Seoul with Advanced Sterile Systems
Dr. Ijeoma Esther Nnamdi: Redefining Global Leadership, Empowering Women and Next-Generation Leaders
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release5 days ago
CVMR at the Future Minerals Forum FMF 2026
-
Press Release2 days ago
Knybel Network Launches Focused Growth Campaign to Help Southeast Michigan Buyers and Homeowners Win in a Competitive Housing Market
-
Press Release6 days ago
South Africa’s 2026 Event Landscape Signals Shift Toward Experience-Driven Participation, Finds Events Guys
-
Press Release6 days ago
BiFinance to List MASK-USDT Trading Pair, Expanding Community-Driven Asset Offerings
-
Press Release4 days ago
Valencia Scientology Mission Highlights Volunteer Humanitarian Work in La Llum
-
Press Release4 days ago
Highly Recommended by GoodNight New York: Zeagoo Patterned Shirt Becomes the Focal Point of Early Spring Outfits
-
Press Release7 days ago
David Hoffmeister: A Global Spiritual Voice Transforming Lives Through A Course in Miracles
-
Press Release2 days ago
New Findings Reveal a Hidden Indoor Air Quality Crisis Linked to Aging HVAC Systems and Fiberglass Ductwork Across South Florida